| 摘要: |
| 目的：探讨降气平喘方含药血清对哮喘大鼠气道平滑肌细胞(ASMC)中易感基因解整合素金属蛋白酶 33（ADAM33）和E26 转录因子-1（ETS-1）表达的影响及其作用机制。方法：通过卵清蛋白(OVA)致敏建立大鼠哮喘模型，另取SD雌性大鼠分组（降气平喘方组、孟鲁司特钠组）灌胃给药制备不同浓度的含药血清，即降气平喘方组血清分别配制为浓度5%、10%、15%的中药含药血清培养液，孟鲁司特钠组血清配制为30%浓度的西药含药血清培养液，分别对体外培养的ASMC进行同化干预24h。采用CCK8法测定不同含药血清对ASMC生长的抑制率，ELISA法检测各组细胞培养上清液中转化生长因子-β1(TGF-β1)、白细胞介素-6(IL-6)的浓度，Western Blot法检测各组细胞中ADAM33、ETS-1蛋白表达情况。结果：培养出的细胞在细胞免疫荧光检测下鉴定成功；5%和10%中药血清组均能明显抑制ASMC的增殖(P<0.05或P<0.01)；ASMC培养上清液中，10%中药血清组的TGF-β1和IL-6浓度较哮喘模型组明显降低(P<0.05)；与哮喘模型组比较，10%中药血清组对ADAM33蛋白的高表达下调作用更显著（P<0.01），10%、15%中药血清组及30%西药血清组对ETS-1蛋白的高表达下调更显著（P<0.01）。结论：降气平喘方可通过调控ADAM33和转录因子ETS-1表达，减少炎性细胞介质TGF-β1和IL-6释放以及改善气道重塑，达到干预和治疗哮喘的作用。 |
| 关键词: 哮喘 降气平喘方 气道平滑肌细胞 易感基因 气道重塑 |
| DOI： |
|
|
| Effect of Jiangqi Pingchuan prescription on the expression of a disintegrin and metalloprotease 33 and E26 transformation-specific 1 in airway smooth muscle cells of rats with asthma |
| HE Siyu,ZHU Qinquan,ZHANG Di |
| (The First Traditional Chinese Medicine Clinical College of Hunan University of Chinese Medicine，Changsha 410007，Hunan，China;The First Affiliated Hospital of Hunan University of Chinese Medicine，Changsha 410007，Hunan，China) |
| Abstract: |
| Objective：To investigate the effect of serum containing Jiangqi Pingchuan prescription on the expression of the susceptibility genes a disintegrin and metalloprotease 33 (ADAM33) and E26 transformation-specific 1 (ETS-1) in airway smooth muscle cells (ASMCs) of rats with asthma and its mechanism of action.Methods：Ovalbumin sensitization was used to establish a rat model of asthma，and female Sprague-Dawley rats were divided into Jiangqi Pingchuan prescription group and montelukast sodium group and were given drug-containing serum at different concentrations.The serum containing 5%，10%，and 15% Jiangqi Pingchuan prescription was prepared for the Jiangqi Pingchuan prescription group，and the serum containing 30% montelukast sodium was prepared for the montelukast sodium group.ASMCs cultured in vitro were assimilated and intervened using the drug-containing serums for 24 hours.CCK8 assay was used to measure the inhibition rate of different drug-containing serums on the growth of ASMCs；ELISA was used to measure the concentration of transforming growth factor-beta 1 (TGF-β1) and interleukin-6 (IL-6) in the supernatant of each group；Western blot was used to measure the protein expression levels of ADAM33 and ETS-1 in cells.Results：The cells cultured were successfully identified by cellular immunofluorescence technique.The serum containing 5% and 10% Jiangqi Pingchuan prescription significantly inhibited the proliferation of ASMCs (P<0.05 or P<0.01).In the supernatant of ASMCs，the 10% Jiangqi Pingchuan prescription group had significant reductions in the concentration of TGF-β1 and IL-6 compared with the asthma model group (P<0.05).Compared with the asthma model group，the 10% Jiangqi Pingchuan prescription group had significantly greater downregulation of the high expression level of ADAM33 protein (P<0.01)，and the 10% and 15% Jiangqi Pingchuan prescription groups and the 30% Western medicine group had significantly greater downregulation of the high expression level of ETS-1 protein (P<0.01).Conclusion：Jiangqi Pingchuan prescription can reduce the release of the inflammatory cytokines TGF-β1 and IL-6 and improve airway remodeling by regulating the expression of ADAM33 and the transcription factor ETS-1，thereby exerting an interventional and therapeutic effect on asthma. |
| Key words: asthma Jiangqi Pingchuan prescription airway smooth muscle cells susceptibility gene airway remodeling |
